[
  {
    "ts": "2025-12-03T06:57:45+00:00",
    "headline": "Goldman Sachs Maintains Price Target on Amgen (AMGN) Before Key Trial Readouts",
    "summary": "Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 price target and Buy rating for Amgen Inc. (NASDAQ:AMGN) on November 25 ahead of two Phase 2 updates for the company’s obesity medication MariTide, which are anticipated by year’s end. Following previously disclosed induction results from Part […]",
    "url": "https://finance.yahoo.com/news/goldman-sachs-maintains-price-target-065745924.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "928d87e3-614a-39fe-a77b-0f585af95483",
      "content": {
        "id": "928d87e3-614a-39fe-a77b-0f585af95483",
        "contentType": "STORY",
        "title": "Goldman Sachs Maintains Price Target on Amgen (AMGN) Before Key Trial Readouts",
        "description": "",
        "summary": "Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 price target and Buy rating for Amgen Inc. (NASDAQ:AMGN) on November 25 ahead of two Phase 2 updates for the company’s obesity medication MariTide, which are anticipated by year’s end. Following previously disclosed induction results from Part […]",
        "pubDate": "2025-12-03T06:57:45Z",
        "displayTime": "2025-12-03T06:57:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7f9c2455370031b006610a9356c93e99",
          "originalWidth": 176,
          "originalHeight": 132,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HM2fsOdbiFEuf54zfikZNA--~B/aD0xMzI7dz0xNzY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7f9c2455370031b006610a9356c93e99.cf.webp",
              "width": 176,
              "height": 132,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Za1dFHhXzBt70WD5PZUc9w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7f9c2455370031b006610a9356c93e99.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/goldman-sachs-maintains-price-target-065745924.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/goldman-sachs-maintains-price-target-065745924.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T14:26:00+00:00",
    "headline": "Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?",
    "summary": "Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.",
    "url": "https://finance.yahoo.com/news/lly-strengthen-lead-glp-1-142600653.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a12adde5-bec3-3c31-8c39-1530d2fdf49a",
      "content": {
        "id": "a12adde5-bec3-3c31-8c39-1530d2fdf49a",
        "contentType": "STORY",
        "title": "Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?",
        "description": "",
        "summary": "Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.",
        "pubDate": "2025-12-03T14:26:00Z",
        "displayTime": "2025-12-03T14:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lly-strengthen-lead-glp-1-142600653.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lly-strengthen-lead-glp-1-142600653.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]